1. Adnot, S., Lefort, J., Lagent, V., Braquet, P., Vargaftig, B. B., 1986, Interference of BN 52021, a PAF-acether antagonist, with endotoxin induced hypotension in the guinea pig,Pharmacol. Rev. 18:197–200.
2. Archer, C. B., Page, C. P., Paul, W., Morley, J., and McDonald, D. M., 1983, Early and late inflammatory effects of PAF-acether in the skin of experimental animals and man,J. Invest. Dermatol. 80:346–347.
3. Archer, C. B., Frohlich, W., Page, C. W., Paul, W., Morley, J., and McDonald, D. M., 1984, Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man,Prostaglandins27:495–501.
4. Baranes, J., Helleganarch, A., Le Hegarat, M., Viossat, I., Auguet, M., Chabrier, P. E., Clostre, F., and Braquet, P., 1986, The effect of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021,Pharmacol. Res. Commun. 8:717–737 (Feb.).
5. Benveniste, J., and Chignard, M., 1985, A role for PAF-acether (platelet activating factor) in platelet-dependent vascular diseases,Circulation72:713–717.